Saturday,
9 August 2025
Australians at risk of shingles have access to a newly funded vaccine

GSK Australia welcomes the listing of Shingrix (Recombinant Varicella Zoster Virus glycoprotein E antigen (AS01B adjuvanted vaccine)) on the National Immunisation Program (NIP) for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in Australia on November 1.

Shingrix is the first non-live vaccine to be listed on the NIP for the prevention of shingles and PHN.

Non-live vaccines ...

There's more to this story... Subscribe to Wangaratta Chronicle.